Please assess the completion status of the following clinical trial:

Trial Title: Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age at randomization: at least 2 months, but less than 6 years of age. Note that children as young as 1 month were screened for the study.~* Diagnosed first or second febrile or symptomatic UTI within 112 days prior to randomization~* Presence of Grade I- IV VUR based on radiographic voiding cystourethrogram (VCUG) performed within 112 days of diagnosis of index UTI.~* Appropriately treated index febrile or symptomatic UTI~Exclusion Criteria:~* Index UTI diagnosis more than 112 days prior to randomization~* History of more than two UTIs prior to randomization~* For patients less than 6 months of age at randomization, gestational age less than 34 weeks~* Co-morbid urologic anomalies~* Hydronephrosis, SFU Grade 4~* Ureterocele~* Urethral valve~* Solitary kidney~* Profoundly decreased renal size unilaterally on ultrasound (based on 2 standard deviations below the mean for age and length) performed within 112 days after diagnosis of index UTI~* Multicystic dysplastic kidney~* Neurogenic bladder~* Pelvic kidney or fused kidney~* Known sulfa allergy, inadequate renal or hepatic function, Glucose-6-phosphate dehydrogenase deficiency or other conditions that are contraindications for use of TMP-SMZ~* History of other renal injury/disease~* Unable to complete the study protocol~* Congenital or acquired immunodeficiency~* Underlying anomalies or chronic diseases that could potentially interfere with response to therapy such as chronic gastrointestinal conditions (i.e., malabsorption, inflammatory bowel disease), liver or kidney failure, or malignancy.~* Complex cardiac disease as defined in the Manual of Procedures.~* Any known syndromes associated with VUR or bladder dysfunction~* Index UTI not successfully treated~* Unlikely to complete follow-up~* Family history of anaphylactic reaction to sulfa medications

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 71 Months
- Healthy Volunteers: f

Study Arms:
- Trimethoprim-Sulfamethoxazole (Type: ACTIVE_COMPARATOR): Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.
- Placebo (Type: PLACEBO_COMPARATOR): Cherry-flavored liquid suspension matched to active comparator.

Based on this trial design, predict the completion outcome and termination type (if applicable).